<SEC-DOCUMENT>0001564590-21-057142.txt : 20211116
<SEC-HEADER>0001564590-21-057142.hdr.sgml : 20211116
<ACCEPTANCE-DATETIME>20211116063055
ACCESSION NUMBER:		0001564590-21-057142
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211111
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211116
DATE AS OF CHANGE:		20211116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		211414056

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>txmd-8ka_20211111.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-16T00:39:49.9286903+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 9fe31145c973496888a3ea2e1faedf30 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:txmd="http://www.therapeuticsmd.com/20211111" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
txmd-8ka_20211111.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000000" name="dei:AmendmentFlag" contextRef="C_0000025743_20211111_20211111">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000002" name="dei:EntityCentralIndexKey" contextRef="C_0000025743_20211111_20211111">0000025743</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="txmd-20211111.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000025743_20211111_20211111">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-11</xbrli:startDate>
					<xbrli:endDate>2021-11-11</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Washington, D.C.&#160;&#160;20549</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:9pt;text-transform:uppercase;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:14pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">FORM <ix:nonNumeric id="F_000003" name="dei:DocumentType" contextRef="C_0000025743_20211111_20211111">8-K/A</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(d) OF THE</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECURITIES EXCHANGE ACT OF 1934<br /></p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Date of Report (Date of earliest event reported): <span style="text-transform:none;"><ix:nonNumeric id="F_000004" name="dei:DocumentPeriodEndDate" contextRef="C_0000025743_20211111_20211111" format="ixt:datemonthdayyearen">November 11, 2021</ix:nonNumeric></span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2qrvzx0ul1b000001.jpg" title="" alt="" style="width:222px;height:31px;" /></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:270pt;;">
<tr>
<td style="width:270pt;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0000025743_20211111_20211111">THERAPEUTICSMD, INC.</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000025743_20211111_20211111" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></p></td>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityFileNumber" contextRef="C_0000025743_20211111_20211111">001-00100</ix:nonNumeric></p></td>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000025743_20211111_20211111">87-0233535</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation)</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer<br />Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:270pt;;">
<tr>
<td style="width:270pt;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000025743_20211111_20211111">951 Yamato Road</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0000025743_20211111_20211111">Suite 220</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0000025743_20211111_20211111">Boca Raton</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressStateOrProvince" contextRef="C_0000025743_20211111_20211111">FL</ix:nonNumeric> <ix:nonNumeric id="F_000013" name="dei:EntityAddressPostalZipCode" contextRef="C_0000025743_20211111_20211111">33431</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Office) (Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code:&#160;&#160;<span style="font-weight:bold;"><ix:nonNumeric id="F_000014" name="dei:CityAreaCode" contextRef="C_0000025743_20211111_20211111">(561)</ix:nonNumeric></span> <span style="font-weight:bold;"><ix:nonNumeric id="F_000015" name="dei:LocalPhoneNumber" contextRef="C_0000025743_20211111_20211111">961-1900</ix:nonNumeric></span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:270pt;;">
<tr>
<td style="width:270pt;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:WrittenCommunications" contextRef="C_0000025743_20211111_20211111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SolicitingMaterial" contextRef="C_0000025743_20211111_20211111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementTenderOffer" contextRef="C_0000025743_20211111_20211111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000025743_20211111_20211111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of Each Class</p></td>
<td valign="middle" style="width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="middle" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Each Exchange on Which Registered</p></td>
</tr>
<tr>
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0000025743_20211111_20211111">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td>
<td valign="top" style="width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0000025743_20211111_20211111">TXMD</ix:nonNumeric></p></td>
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0000025743_20211111_20211111" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2).</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:9pt;margin-right:6.67%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000023" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000025743_20211111_20211111" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Times New Roman';"><span style="font-size:10pt;font-family:'Times New Roman'">&#9744;</span></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXPLANATORY NOTE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000001" name="dei:AmendmentDescription" contextRef="C_0000025743_20211111_20211111"><p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 12, 2021, <span style="Background-color:#FFFFFF;">TherapeuticsMD, Inc., a Nevada corporation (the "Company"), </span><span style="color:#000000;">filed a Current Report on Form 8-K (the &#8220;Original 8-K&#8221;) </span>to announce that on November 11, 2021, the <span style="Background-color:#FFFFFF;">Company </span>issued a press release, <span style="color:#000000;">provided a slide presentation and held a webcast and conference call </span>announcing its financial results for the third quarter ended September 30, 2021 <span style="color:#000000;">(the &#8220;Earnings Call&#8221;)</span>. This Amendment No. 1 to the Original 8-K <span style="color:#000000;"> is being filed solely to furnish the transcript from the Earnings Call.</span></p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-9.07%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 2.02</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Results of Operations and Financial Condition.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.33%;">See information provided in Item 7.01.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-9.07%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Regulation FD Disclosure.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.33%;"><span style="color:#000000;">On November 11, 2021, the </span><span style="Background-color:#FFFFFF;color:#000000;">Company </span><span style="color:#000000;">issued a press release and</span> provided a slide presentation, each of which were previously furnished with the Original 8-K<span style="color:#000000;">. </span>Also on November 11, 2021, the Company held the Earnings Call. A copy of the transcript from the Earnings Call is furnished as Exhibit 99.1 and is incorporated by reference herein. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements and Exhibits.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;&#160;&#160;</p></td>
<td colspan="2" valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exhibits</p></td>
<td valign="top" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Exhibit Index</span></p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Exhibit No.</span></p></td>
<td colspan="2" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description </span></p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td colspan="2" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="txmd-ex991_16.htm"><span style="text-decoration:underline;">Transcript of Earnings Conference Call on November 11, 2021.</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td colspan="2" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><br /></span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">SIGNATURES</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&#160;&#160;November 16, 2021</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THERAPEUTICSMD, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James C. D&#8217;Arecca</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James C. D&#8217;Arecca</p></td>
</tr>
<tr>
<td valign="top" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>txmd-ex991_16.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
txmd-ex991_16.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:102.5%;">
<tr>
<td style="width:102.5%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E6E6E6" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TherapeuticsMD (2021 Q3 Earnings)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">November 11, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Speakers:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Lisa Wilson; TherapeuticsMD; Investor Relations </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Rob Finizio; TherapeuticsMD, Inc.; Co-Founder, CEO &amp; Director</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Hugh O&#8217;Dowd; TherapeuticsMD, Inc.; President</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">James D&#8217;Arecca; TherapeuticsMD, Inc.; CFO</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Mark Glickman; TherapeuticsMD, Inc.; Chief Business Officer</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participants:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Louise Chen; Cantor Fitzgerald &amp; Co.; Senior Research Analyst &amp; MD</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Annabel Samimy; Stifel, Nicolaus &amp; Company, Incorporated; MD</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Douglas Tsao; H.C. Wainwright &amp; Co, LLC; MD &amp; Senior Healthcare Analyst</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:102.5%;">
<tr>
<td style="width:102.5%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E6E6E6" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRESENTATION</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:&nbsp;&nbsp;Good morning, ladies and gentlemen. Thank you for joining us for the TherapeuticsMD Third Quarter 2021 Financial Results Conference Call. (Operator Instructions)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I would now like to turn the call over to Lisa Wilson, Investor Relations for TherapeuticsMD. Lisa?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lisa Wilson:&nbsp;&nbsp;Thank you, operator. Good morning, everyone, and thank you for joining today to discuss our third quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing our third quarter financial results. The press release and accompanying presentation are available on the company's website, therapeuticsmd.com in the Investors and Media section.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On today's call from TherapeuticsMD are Chief Executive Officer, Rob Finizio; President, Hugh O'Dowd, Chief Financial Officer, James D&#8217;Arecca; and Chief Commercial Officer, Mark Glickman.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I would like to remind everyone that certain statements made during this conference call may be forward-looking statements. Such forward-looking statements are based upon current expectations, and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors and risks, some of which are identified in our press release and our annual, quarterly and other reports filed with the SEC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements are based on information available to TherapeuticsMD today, and the company assumes no obligation to update these statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the company's website. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on November 11, 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With that, I'll turn the call over to TherapeuticsMD's CEO, Rob Finizio.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rob Finizio:&nbsp;&nbsp;Good morning, everyone, and thank you for joining our third quarter call. We look forward to updating you on the steady growth of our top line sales, but before going into further detail, I have an important announcement to make.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More than a year ago, I started a search for a company president who had the necessary financial and commercial expertise, the right personality and the right strategic vision of someone who would eventually be my successor as the new CEO of TherapeuticsMD. Back in August, after a comprehensive and exhaustive search process, we hired Hugh O'Dowd to fill the role as our President.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh is a first-class professional with proven leadership and entrepreneurial skills and deep industry knowledge, having held leadership positions at both large and small pharmaceutical companies. The Board of Directors and I have worked closely with Hugh since August to ensure he developed an in-depth understanding of TherapeuticsMD. Now I'm happy to announce that the Board of Directors have unanimously elected Hugh O'Dowd as Chief Executive Officer and member of the Board of Directors on or before December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After being at the helm of TherapeuticsMD since its inception 13 years ago, I will now transition to Vice Chairman of the Board of Directors and will now focus on Board-level strategic direction of the company. I'm confident in Hugh&#8217;s abilities to achieve our next milestone of EBITDA breakeven in the back half of 22 and building TherapeuticsMD into the premier women's health company in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With that being said, I'd like to congratulate you and ask Hugh to take over the call. Hugh?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;Thank you, Rob, and good morning, everyone. First, I wish to express my thanks and appreciation to Rob Finizio and our Board of Directors. Rob, this organization wants to thank you for your leadership in founding the company and launching a portfolio of 3 innovative and well-differentiated therapies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TherapeuticsMD would not be where it is without your dedication, vision and leadership. I see enormous opportunity for the company and will invest all my energy in realizing our goal to become the premier women's health care company by serving our mission, empowering women of all ages through better health care.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By way of background, I was most recently CEO of Neon Therapeutics for 4 years, a clinical stage immuno-oncology company that was sold to BioNTech SE last year. Prior to this, I enjoyed a 20-year career in a variety of ascending senior leadership roles at Novartis, which included Country President, Region Head and Chief Commercial Officer </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Oncology Hematology business unit, then the second largest oncology business in the world. I am deeply committed to our mission and serving women, an ambition, which has its roots reaching back 3 decades to my first launch as a marketer in the metastatic breast cancer setting.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">My philosophy was shaped by these initial series of launch experiences, where great science must focus on clearly defined underserved patient populations in need of innovation. I look forward to sharpening this focus exclusively on women of all ages as we seek to improve their overall health. While serving our patient and health care professional communities remains my priority, it's also important that we deliver results to our shareholders, starting with achieving positive EBITDA in the second half of 2022. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We'll accomplish this by embracing financial discipline, which is why we are announcing today, a significant cost savings initiative that will reduce our annual costs in 2022 by at least $40 million. This figure does not include savings from or the costs associated with a potential divestiture of VitaCare estimated at approximately $20 million. In addition, we've already streamlined our senior leadership structure by eliminating 3 executive roles.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Last month, we announced the appointment of Mark Glickman, who will now be serving as our Chief Commercial Officer. Under Mark's organization, we now have a new head of sales, a new head of marketing and a new Head of Market Access. As you'll see in a few moments, this team has already produced results, and they are executing plans with a renewed focus on health care professionals. And finally, we are also actively working to address our capital structure to allow for more financial flexibility and ease the restrictive revenue and cash covenants that are currently in place.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, I'm thrilled to be joining and leading TherapeuticsMD. My immediate priorities are: drive top line growth and overall operating performance. The elimination of at least $60 million of annual costs, including the successful divestiture of VitaCare, which we believe will then enable us to achieve EBITDA breakeven in the second half of 2022. And finally, to address our capital structure to ease the restrictive revenue and cash covenants currently in place. To maintain accountability, we will provide full year guidance starting in the first quarter of 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I look forward to taking your questions at the end of the call. And now I'll turn it over to our Chief Financial Officer, James D&#8217;Arecca, to discuss our financial results in greater detail. James?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James D&#8217;Arecca:&nbsp;&nbsp;Thanks, Hugh, and good morning, everyone. Slide 6 shows a snapshot of our quarterly net product revenue trends, which continue to increase as we emerge from the COVID-19 pandemic. Our net product revenue for the third quarter was $24.5 million, of which $23.1 million was applicable toward our third quarter revenue covenant, which was successfully achieved. As compared to the third quarter of 2020, our net product revenue increased by 41%.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For ANNOVERA, net revenue increased by 84% as compared to the third quarter of 2020 to $11.8 million. This increase was driven by strong volume growth, partially offset by a slight decrease in net price as compared to the third quarter of 2020. Net price per unit of ANNOVERA remained stable as compared to the second quarter of 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The volume increases for ANNOVERA this quarter reflected additional stocking in our wholesaler and pharmacy channels in advance of expected increased patient demand due to new insurance coverage beginning in the fourth quarter and our recently assigned J Code, which brings significant additional patient access in the public health sector. IMVEXXY net revenue increased by 17% as compared to the third quarter of 2020 to $8 million. This increase was mainly attributable to higher net pricing, partially offset by a moderate decrease in sales volumes shipped to customers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Let me share some highlights from our financial statements on Slide 7. Our gross profit margin was 79% in the third quarter of 2021 and gross profit margins were negatively impacted by approximately $700,000 of BIJUVA export sales, which were recorded in the third quarter and were sold at cost. Total operating expenses of $60 million for the third quarter of 2021 included approximately $7.2 million of severance-related expenses attributable to the exit of 4 executives. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absent these severance-related expenses, our total operating expenses were in line with our expectations as we continue to invest behind ANNOVERA and IMVEXXY. We expect our operating expenses to decrease in the fourth quarter to below $50 million, excluding the impact of any onetime costs related to our 2022 cost savings initiative. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Next year, as Hugh mentioned a moment ago, we expect to reduce our annual operating expenses by at least $60 million, assuming the divestiture of VitaCare. Net cash used in operating activities was $38.2 million for the third quarter. And as of September 30, 2021, we had $104.8 million in cash.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I'll now turn the call over to our new Chief Commercial Officer, Mark Glickman, to provide more detail around our commercial progress. Mark?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Glickman:&nbsp;&nbsp;Thanks, James, and good morning, everyone. I'm excited to be on this call.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we delve into the company's commercial activities, I wanted to give you all a quick summary of my background. This is my 31st year in the health care industry. I started my career with large pharmaceutical companies before transitioning into the smaller, more entrepreneurial realm. As an executive with Kos Pharmaceutical, I helped the company grow from minimal revenue to over $1 billion in sales. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And at Auxilium, we increased our market cap from $900 million to a $3 billion sale to Endo in just 3 years. Most recently, our Chief Commercial Officer at Esperion Therapeutics where we introduced a novel cholesterol product directly into the global pandemic. You can see more details about my background on Slide 9.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stepping into my role of Chief Commercial Officer. I contemplated the overall vision for TherapeuticsMD and saw 3 key factors that I believe will drive long-term success. First and foremost, our focus must remain on the patients and physicians. Second, an environment of accountability is crucial. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And this is something we've already implemented. This organization is focused on meeting the needs of our patients, physicians and our shareholders. Third, we've begun creating a performance-based organization to execute with excellence on our overall objectives. These moves are designed to help us achieve our ultimate goal to become the premier women's health care organization.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At TherapeuticsMD, we have 3 differentiated therapeutic options for women. Since joining and looking back, I saw an opportunity to address our overall commercial focus. Our approach, while appropriate during the pandemic has been adjusted, and we are now well on our way to transitioning to a health care practitioner prioritized effort. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After some internal changes, I believe we have the right people and the team is fully committed to the success of the company. With this refreshed commercial team in place, we have removed several barriers to launch and importantly, have seen significant wins with managed care, which we'll talk about in a few slides.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the assessment I conducted, I determined we could improve sales by redirecting marketing programs. These programs are overweighted to the consumer and have now shifted to the health care provider. We also simplified the data orientation for the sales organization, which is designed to improve our ability to effectively execute. Finally, while we continue to have good managed care reach, we are redirecting our immediate focus to the opportunities where we believe we have the greatest impact as soon as possible.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physician targeting became my first priority as we redistributed our activity to the highest decile prescribers. This effort, given the size of the rollout continues to progress in stages, while the evaluation of call and field activity is ongoing. As my second priority, we needed to refocus our sales representatives on solution selling. The key to the sales tactic is to make the salesperson the center of the solution process. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most branded pharmaceutical products, despite great coverage, present some level of complexity regarding patient access. We have many great solutions to assist patients and physicians. I've asked our sales representatives to proactively discuss potential issues and align the appropriate solutions, ensuring patients receive our products at affordable prices. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, we refined the focus to provide direction and tools that are designed to result in sustainable, consistent growth. I'm excited for the opportunities for success and recognize there's still much to do. I'm confident that with this refined focus and a reemphasis on accountability, we will be able to recognize the opportunities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So what were the results so far during my tenure. First, the culture of accountability and close evaluation of performance resulted in an immediate increase in calls per day to targeted physicians, specifically those in the highest decile. Overall calls today have moved up from the low 8s to the low 9s. This is a critical gauge of effort. The next slide shows that these extra calls went to the correct targets. In September, 53% of our effort was through the top 4 deciles physicians who represent 40% of the market. This is the first time we've broken 50% and it was a 10% increase over August, which is great progress in only 1 month.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">How does this impact prescriptions. On Slide 17, you'll see total monthly prescriptions for ANNOVERA, our long-lasting reversible contraceptive for women. To the left, in purple, are several quarters of relatively flat activity. In the June to July time frame, we implemented our changes in earnest, which accounts for the improvement beginning in August and really taking off in September. In September, we exceeded 3,000 monthly total prescriptions of ANNOVERA for the first time. On a quarterly basis, we saw an increase of over 1,000 prescriptions of ANNOVERA quarter-over-quarter or 14% jump, driven almost entirely by the success in September.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slide 19 shows another indicator of our productivity in that cumulative prescribers increased over 8,100 for the quarter plus 1,300 new prescribers, most of which were in that higher decile area. This overall uptick is a result of the changes in our focus and our sales organization.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning now to IMVEXXY, which is an estrogen hormone therapy for postmenopausal patients suffering from VVA. We are very pleased with the IMVEXXY results because this quarter, while we prioritized ANNOVERA with the aforementioned HCP and targeting initiatives, we did not lose IMVEXXY traction. Currently, we're performing a full targeting and mix assessment, which should be completed by the end of the fourth quarter and fully implemented early next year. This will give us some of the insights we were able to achieve with ANNOVERA. As we move into 2022, we expect IMVEXXY to return to being a growth product for the company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I want to stress that while we did transition most of our resources to a health care practitioner focus, we still enjoyed a very successful consumer campaign. The comedian and actress Whitney Cummins continues to be an outstanding spokesperson for us and her advocacy as an ANNOVERA user is influencing the right target audience. We also continue to see consumer appreciation and activities around the various IMVEXXY campaigns. We are encouraged by the benefits and the changes I discussed have already produced.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Looking forward, we believe there are additional accelerators not reflected in the slides I just showed. We have had significant managed care wins that will take place predominantly in the fourth quarter, and a J Code was recently assigned, which gives ANNOVERA access to a significant piece of the public health sector. We also filled the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22 vacancies in our field force with high-quality representatives who hit the field the first week in October.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We're entering into an exciting new phase for the company. I'm highly optimistic about TherapeuticsMD's future, and I look forward to speaking with you next quarter. And now, operator, please open up the call for questions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:102.5%;">
<tr>
<td style="width:102.5%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E6E6E6" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QUESTIONS AND ANSWERS</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:&nbsp;&nbsp;(Operator Instructions) Our first question comes from the line of Louise Chen with Cantor Fitzgerald.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louise Chen:&nbsp;&nbsp;Thank you for taking my questions here. So I have had a few that are coming in for me, and I wanted to ask you. So first question is why the CEO change now? I know you've been looking for a while. Is there any sort of inflection points that are driving your decision here? And then secondly, Hugh, what are you going to do differently from what Rob did, do you have a new strategic vision for the company? </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And then just some housekeeping items in terms of the SG&amp;A progression next year. Did you say that you'll be at less than $50 million of spend by the fourth quarter '21 and that will ramp down from there? And should we assume that you'll sell VitaCare next year and take out that $20 million as well or just kind of stick right now with the $40 million decrease in SG&amp;A?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;So Louise, it&#8217;s great to meet you. Let's unpack that because there's 3 good segments and questions. We'll start with Rob in a moment because I think that's helpful for context of why now and the considered process. Then I'll pick up and offer comment as it relates to the priorities, and then we'll finish up, I think with James as it relates to the VitaCare piece, in particular, but Rob?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rob Finizio:&nbsp;&nbsp;Thanks, Hugh. Louise, thanks for the question. So as far as my role, so look, I remain fully committed to TXMD. I'm not going anywhere. I've changed my role to Vice Chairman and as Hugh takes over all operational accountability for TXMD, I'm going to focus on strategic Board level focuses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And I have no plans currently to sell any of my stock or shares and am still probably one of the largest, if not the largest shareholder. So rest confidently that I am still fully committed here and still see a fantastic opportunity here. We did start this process over a year ago, right? And I met Hugh a full year ago, and we were looking for somebody with the right commercial background, the right financial discipline and really the right operating history, which we all found in Hugh. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And when we hired them as the President to ensure that he was as good as advertised, and that he could come in and operate the way we thought he could. And I'll tell you, he's met all of those criteria. And the Board has unanimously voted them in, and I'm really excited </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for my next chapter here, and I'm really excited for Hugh. And I think we've got a winner, and I hope that answers your question. I'll turn it back to Hugh.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;Thank you, Rob. And by the way, it's a great kind of view. Louise, we really took the opportunity to emphasize what are the company's immediate priorities and why I really took an effort to emphasize the 4 points. Number one, we've got 3 tremendous well-differentiated assets and driving top line performance and growth is job 1. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And the operating performance surrounding that is where really our focus lies. It was important to align the cost structure with that top line evolution. And it was reasonable for us to consider how we should eliminate $60 million in full '22 cost structure, inclusive of the divestiture of VitaCare. And I think James could offer some additional comment there. But doing so, really does secure our pathway to EBITDA breakeven in the second half of '22. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That is a clear mission for this company. It's a clear mission with the Board of Directors, and I will see to it that we deliver. And then finally, how do we frankly do address our capital structure and these restrictive covenants that are in place? These 4 things are top priorities and are my focus. And beyond that, as I shared in the call. In Q1, we'll issue full year guidance. And I look forward to elucidate further beyond that period. But let me turn it over to James to your third query, Louise, as it related to VitaCare.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James D&#8217;Arecca:&nbsp;&nbsp;Yes. Thanks, Hugh. Yes, Louise, you had it right. in your initial question, we are expecting the SG&amp;A to come down next quarter to below $50 million. And then when you think forward to 2022, you can take out at least the $40 million, which is the TXMD portion and then depending on the VitaCare sale and its timing, at least an additional $20 million. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So that would get you to a 2022 estimated SG&amp;A spend. With regard to VitaCare, we do intend to divest it. That's our planning scenario right now. And as Hugh mentioned, we'll be back in the first quarter with guidance, but recognize that we're agile here and are thinking about all the different scenarios that are in front of us.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louise Chen: Thank you.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:&nbsp;&nbsp;Our next question comes from the line of Annabel Samimy with Stifel.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annabel Samimy:&nbsp;&nbsp;A lot of change here. So congratulations on this new shift. I had several here. On -- I guess, my big question primarily is your first priority is driving top line performance. These products have now been in the marketplace for a couple of years, specifically IMVEXXY. Also, last quarter, you went from, I guess, going from a consumer focus. Now you're focusing again on HCPs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">But I guess my question here being that they've been around for some time, what does the HCP not know at this point about this product? Like what are the chances for inflection </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because it seems like the managed care coverage was pretty solid, has been solid for a while. And so what is the physician community not getting about these products yet</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">?</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A second question on cost savings. What exactly is being sacrificed from a cost savings perspective? </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">What should we expect? Is it DTC? Is it something else? If you can help us sort of frame that, please? And then on capital structure, alleviate the capital structure, what options do you have available to essentially adjust your balance sheet to give yourself some breathing room here?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;All right. Thank you for those queries, Annabel. Excellent questions. We're going to have Mark Glickman, our Chief Commercial Officer, answer the first piece. But one of the things I took note that I enjoyed in his presentation of a few moments ago, is that performance in the early shoots that we saw that, frankly, revealed growth is really driven by the inputs and changes that he's already erected comes in the absence of new items that are coming online now in the fourth quarter. And I think when we rebalance in a more open world post-COVID, we foresee a real opportunity to take advantage of those catalysts. Mark, would you care to elaborate?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Glickman:&nbsp;&nbsp;Sure. Nice to talk to you again, Annabel. It's been a while. So regarding IMVEXXY and the health care practitioner focus, while your statement is correct, the HCPs know about IMVEXXY quite a bit. However, there's a lot of options out there for women and reminders and consistent communication and education about certain patient types, the reminder, the consistent reminder to the physician as to who is the proper IMVEXXY patient. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The physicians tend to forget, and especially throughout COVID, they'll tend to go towards generic products. They'll tend to go towards products that they used many years ago and IMVEXXY actually being fairly on the new side, we do need to continue that awareness. In fact, awareness is the #1 driver of prescribing of branded products in the industry. So it's not necessarily education, what are they going to learn new. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It's about the patient type, it's about continuing awareness and also making sure the entire office is aware how to prescribe IMVEXXY, what questions they may receive from the patients. So unlike ANNOVERA where there is more online interest for the postmenopausal women that are VVA sufferers, they do rely on their health care practitioner and we need to be there. We need to give them awareness, education, samples for the women. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All these things are critical. So I do think this is the most critical attention we can give right now to IMVEXXY. And we're rolling through a new targeting initiative to ensure that we're being as efficient and productive as possible with these new targets. I do anticipate to see this go back into a growth phase in Q1.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;Thank you, Mark. Now let's turn to your second query: is the nature and composition of these cost savings. So we've articulated from a '22 full year perspective, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">savings of at least $60 million. Now $20 million of that is coming at least from the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VitaCare</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> divestiture. So let's park that off to the side. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So that means on what I'll call the TXMD pharma side of the business, there's $40 million coming from there. This is an exercise that is really driven by the shift that Mark has just elucidated. So we're really talking about rebalancing our focus, and lessened our intensity from the DTC media ad buy component of that. we believe while still leveraging that, as Mark noted in his opening remarks, but embracing the impact in power focus and execution of a greater health care professional focus, we acquire synergies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And I think with that financial discipline, we can drive top line growth, we can drive EBITDA positivity and breakeven in the back end of next year. And I think that is just value creation that we can offer. Now as it relates to your third question, I'll turn to James to further go on.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James D&#8217;Arecca:&nbsp;&nbsp;Yes. So that was the one on the cap structure, I believe. I think the first domino that has to fall there is VitaCare. And we'd like to see first, what kind of proceeds are available in that regard. And then once we have that information, then I think it really kind of opens things up in terms of where we head next. You heard Hugh mention we want to address the revenue and cash covenants that we have in our current facility. So we'll certainly be looking at refinancing there. So -- but one thing at a time, let's take the first step, get to the VitaCare answer first, and then we'll take it from there.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annabelle Samimy: Great &#8211; thank you.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:&nbsp;&nbsp;(Operator Instructions) Our next question comes from the line of Douglas Tsao with HC Wainwright.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Douglas Tsao:&nbsp;&nbsp;Just maybe could you just walk through a little bit around the manufacturing change and the manufacturing disruptions for ANNOVERA? And how you are for supply into 4Q and 1Q?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;Doug, thank you for the question. Really, the current problem stems primarily from an extremely narrow FDA-approved release specification that requires us to reject batches that fall upside the release criteria for one specific test method. We have submitted an NDA supplement with FDA with a PDUFA date of December 12, 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So that really provides data, we believe, justify a revision of that specific portion of the specification for that one test method. Now if the FDA approved the NDA supplement in December, we believe we'll be able to release batches that were outside the previously approved specification. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be clear, this submission and potential approval by the FDA would have no impact on our product quality. We foresee a Q4 pathway that would permit satisfying increasing patient demand. But this is the first time that our ability to adequately meet ANNOVERA demand is in question due to the recent increase in batch failures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Douglas Tsao:&nbsp;&nbsp;Okay. And then just as a second question, Mark mentioned accountability a lot. I was just wondering if you could just provide a little bit more of a sense of what he means by that?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;So Mark, would you care to elaborate?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Glickman:&nbsp;&nbsp;Certainly, I mean accountability, when we think about the sales organization, to me, it's having a clear plan, a well-thought-out plan going into a quarter or into the year and executing against that plan. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So as we -- since I've been here and with my team, the new internal team working together, we're much more about giving direction where the representatives could be, where the right targets are and our expectation accountability is to follow call, follow messaging and follow overall accountability with solution selling. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And these are all really items that were not -- are not negotiable. So I don't want to comment about how things were before. But in my environment, everyone is accountable for the -- to execute against the plan as it's rolled out, and we're already seeing that. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So it's about activity metrics, it's about performance metrics, and it's about providing solutions as directed on a consistent basis. Additionally, internally, it's about having programs and plans that are ROI positive and being able to demonstrate that our spend is actually worthwhile and that our spend is actually going to benefit the overall organization, patients and physicians.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;Doug, I just want to say, I can't tell you how pleased I am with the early work done by Mark with our new Head of Sales, our new Head of Marketing, our new Head of Market Access, it's a new day. There is a vibrant energy associated with Mark's leadership, and I look forward to seeing continued results performing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Douglas Tsao:&nbsp;&nbsp;That's really helpful. And then just one quick follow-up. Just in terms of the calls that are being made today, what percent are actually in-person calls versus ones that are virtual details?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Glickman</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:&nbsp;&nbsp;Thanks Doug. Great question. The statistics I put on the screen today are all in-person calls. So we're actually right now only counting in-person calls as a call. Offices have opened up, and we're out there. So the numbers I provided are all in-person office calls.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Douglas Tsao: Thank you so much. That&#8217;s good to hear.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:&nbsp;&nbsp;There are no further questions. I will now turn the call back to Hugh O'Dowd for closing remarks.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hugh O&#8217;Dowd:&nbsp;&nbsp;Thank you, everyone, for a wonderful morning. We look forward to taking further follow-up. We wish you all a very good day. Take care and be well, and Happy Veterans Day.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:&nbsp;&nbsp;Ladies and gentlemen, this concludes today's conference call. Thank you for your participation, you may now disconnect.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g2qrvzx0ul1b000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2qrvzx0ul1b000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O 4X# 2(  A$! Q$!_\0
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M]4+*!QY0Z'^OX4GBS1[?1? R6D(SM==S8Y8]S71:/X7LM)U*[NX02\K97/\
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M8OI3;;81@DK'%^%_!+^'M?U/4GNQ*+TY"*N-O)/]:?XO\"V'BA4G9VM[Z/\
MU=R@^8?6NRVC.<4A0'U_.GS.]R?9JUCRAOA[XM>(6LWB^4VIX(W,&(^N:['P
MKX/T_P *63Q6H9YI>99G.6<UTP11T%'EK1*<FK((THIW.+T/P8^D^,=1US[8
ML@N_^66W[M==,B21-'-M9'!5E;&&S4VP9H* XZ\>])MO4J,4E8\LE^%^H:;J
M<MWX;UR2P20Y:-LD?_7I9OA==:K;3-K>O37MX4(A+$B.,^H6O4M@Y]Z01(!@
M#'TJO:23T,_80MJ>:Z]H3>'OA%=:49EF,2'YP,9RV:P/"W@%-;\)V.IZ;>RZ
M=J0!!FC8X;'KBO7=6T>SUK39M/OD9[>48=0Y!/XBDTC1;+0]-CT^PC:.WC^Z
M"Q8C\35*J^6Q+H)SOT/-3\+=8U.]3^W_ !'+=VZ'(C4MS^=>DZ9IEII%A%8V
MD2QP1+M50/U/O[U?V#W_ #I=HSFHE)LTC2C%Z'!^*_AQ;:[?C4[*X?3]27GS
MH^ WN:Q)/ASXGOXUM]3\62R6O\2(6RP_/FO5MBYSBCRUYZG/O352:$Z,&S$T
M#P[8>'-)6PLHRL0Y8D\N3U)KB=8^%<AUE]3\/ZH^G2R,69%) R3[=O:O4?+7
M/2@1J  ,\>]*,Y)CE2BT>7#X67-]#-)KVM37]R4*PEBVQ#ZXKL/"'A]_#/AZ
M'36G$YC))=1P<UT(C4'( SZT;!CO^=$IRDK,%3C%W1YKX@^&EQ=>(&UG1-6?
M3[F4[I!DXS[8KIO">@7V@Z?)%J&IR7\TK[S)(2<'\:Z7:!VHVC&*.9M:@J:3
MT.-\*>#)/#>KZK?M=B8WS!M@7&W!/^-5_%WP[L?$MPM]#*]IJ2XQ/$.N.F?\
M:[GRU[C/IGM1L&,'GZT*<EJANG%JS/)W^&GB>^46U_XKEDM<_,HW98>^>OXU
MV.F^"M)TSPY-HD43&WG7$K[B&?ZFNGV+Z4;%]!1*I*0HTHQV/*_^%8:MIDS_
M /"/>)9[6W;GR78D+],5J>&_ATVGZRFM:UJ4FI:@A_=NY)"_3->@;!1L%/VD
M[6%[&-[G/^*-";78+6-9A&89A+DCTK:C7RXT7.=J@5/M&,<CZ4FP5-]+#5-*
M3DNHS&3GFL;Q/H9\0:6;-)O*)8'=BMS:!2[1Z4DVM1SIJ<7&6QPB>$]=C4(G
MB)U4#  !Z4X^$]?(Y\1RX_&NXV#&,4NT8Q5^T9S_ %*G_3.*M/ -L9EFU2^G
MOY <@2,2M=?%;QQ(J(H55& !P!4NQ>XS2X%2Y2>YK"A3IZQ0F.*=28I:1L?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>txmd-20211111.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-15T21:28:47.2900918+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 9fe31145c973496888a3ea2e1faedf30 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:txmd="http://www.therapeuticsmd.com/20211111" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.therapeuticsmd.com/20211111" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.therapeuticsmd.com/20211111/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txmd-20211111_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txmd-20211111_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>txmd-20211111_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-15T21:28:47.2900918+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 9fe31145c973496888a3ea2e1faedf30 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>txmd-20211111_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-15T21:28:47.2900918+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 9fe31145c973496888a3ea2e1faedf30 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.therapeuticsmd.com/20211111/role/TemplateLink" xlink:href="txmd-20211111.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="txmd-20211111.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentDescription" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>txmd-8ka_20211111_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="txmd-20211111.xsd" xlink:type="simple"/>
    <context id="C_0000025743_20211111_20211111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2021-11-11</startDate>
            <endDate>2021-11-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000025743_20211111_20211111" id="F_000000">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000025743_20211111_20211111" id="F_000002">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000025743_20211111_20211111" id="F_000003">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000025743_20211111_20211111" id="F_000004">2021-11-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000025743_20211111_20211111" id="F_000005">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000025743_20211111_20211111" id="F_000006">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000025743_20211111_20211111" id="F_000007">001-00100</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000025743_20211111_20211111" id="F_000008">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000025743_20211111_20211111" id="F_000009">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000025743_20211111_20211111" id="F_000010">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000025743_20211111_20211111" id="F_000011">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000025743_20211111_20211111" id="F_000012">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000025743_20211111_20211111" id="F_000013">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000025743_20211111_20211111" id="F_000014">(561)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000025743_20211111_20211111" id="F_000015">961-1900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000025743_20211111_20211111" id="F_000016">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000025743_20211111_20211111" id="F_000017">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000025743_20211111_20211111" id="F_000018">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000025743_20211111_20211111" id="F_000019">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000025743_20211111_20211111" id="F_000020">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000025743_20211111_20211111" id="F_000021">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000025743_20211111_20211111" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000025743_20211111_20211111" id="F_000023">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="C_0000025743_20211111_20211111" id="F_000001">On November 12, 2021, TherapeuticsMD, Inc., a Nevada corporation (the "Company"), filed a Current Report on Form 8-K (the &#x201c;Original 8-K&#x201d;) to announce that on November 11, 2021, the Company issued a press release, provided a slide presentation and held a webcast and conference call announcing its financial results for the third quarter ended September 30, 2021 (the &#x201c;Earnings Call&#x201d;). This Amendment No. 1 to the Original 8-K  is being filed solely to furnish the transcript from the Earnings Call.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140248608975448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">On November 12, 2021, TherapeuticsMD, Inc., a Nevada corporation (the "Company"), filed a Current Report on Form 8-K (the &#8220;Original 8-K&#8221;) to announce that on November 11, 2021, the Company issued a press release, provided a slide presentation and held a webcast and conference call announcing its financial results for the third quarter ended September 30, 2021 (the &#8220;Earnings Call&#8221;). This Amendment No. 1 to the Original 8-K  is being filed solely to furnish the transcript from the Earnings Call.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 11,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -HS<%,4@V3W[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -HS
M<%.97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ VC-P4]$HN'QQ!0  >A,  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -HS
M<%.?H!OPL0(  .(,   -              "  ;0-  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ VC-P4Y>*NQS     $P(   L              ( !D!
M %]R96QS+RYR96QS4$L! A0#%     @ VC-P4QPX9>H_ 0  / (   \
M         ( !>1$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -HS<%,D
M'INBK0   /@!   :              "  >42  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( -HS<%-ED'F2&0$  ,\#   3
M      "  <H3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' !05      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="txmd-8ka_20211111.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" original="txmd-8ka_20211111.htm">txmd-8ka_20211111.htm</File>
    <File>txmd-20211111.xsd</File>
    <File>txmd-20211111_lab.xml</File>
    <File>txmd-20211111_pre.xml</File>
    <File>txmd-ex991_16.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g2qrvzx0ul1b000001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "txmd-8ka_20211111.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "txmd-8ka_20211111.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20211111_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20211111_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20211111.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "txmd",
   "nsuri": "http://www.therapeuticsmd.com/20211111",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-8ka_20211111.htm",
      "contextRef": "C_0000025743_20211111_20211111",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AmendmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-8ka_20211111.htm",
      "contextRef": "C_0000025743_20211111_20211111",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AmendmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description",
        "terseLabel": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "verboseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "verboseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.therapeuticsmd.com/20211111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001564590-21-057142-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-057142-xbrl.zip
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MTN%3)^QWP"XX(<U^;SZ4Z,!.<[;%F7TG;AY6<%ZF3'V3&ZIR*\B3KSS\2EN
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M64PP'\7W-UYPR)R0WUTVK:X_(9\'V6X?8INW2Q)#JX^NK"$UM(96;,$ZYZA
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M)74S-!VD5B;2)Z[$D?Q"M.04CK\D[/1_4$L#!!0    ( -HS<%,^52C^*04
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M\JN0;JO7!_+A _,B:'T5S**![P(T_%:@82U QW0UC'!IX-.'Z'9<#'K&2 V
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M=&WM?6MSVT:R]O>M.O\!QTG6>ZHH6K*=FYUL2I&=6#F.E=B*O?GTUA 8DHA
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MEVK#EOK=PP,VX;'I1 (Y;'J\H6WYA8RCF3,[<P+-C)@=S%.V9YX1\X)]/M'
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M_9%!X&I--P7)>)W\P+SH>6 H1;&9!+8!>6'25F0;8DP*DJ'CPQXWK&]J:CJ
M170P<$%1L*N^@0//1IQJ7MC7.;O:Q2_"&$\%K;9-GLKQ@5>]$U=8:AR\X?2%
M..# D=CM(0C9@ATH]-;IZ+'8"PM=)JY;T?20^GY[!4<0'2'1OND,>1R']WI=
MC6!,$U+H<CI4&;BTUS0XPZJQ#Y*L8?GA(1N*Y&"_JVH\DA["-&L;AI+2>9=8
M9V"K$L7I!<LG@8OS]Y$@FJA,\7Y7C>7/NVO%A9>4:X##"@[WK#7N7B9$;4"
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M8-7/9)=L"-"F2>8I9V5Z8O>>:%((& $KF@1\'7GIDU!3-N\6L*EH:<O8F*B
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M:#C0AZ>,7M-] $+QLN]TE[)?]<W^4L2RB*WG;0AE<4JQYNR/YV@?4+,DT@E
MZ-+V*4M]F9.(\'N.*,#G4G=@@3 69]4 SD+<D/;7AQXY=+Z),-/>CF+PTKTC
MA2][F1Y'KWWFY33*.J9[%,3,VH?D5UZ75>GS!/N,M)!"SEX,I&2"&?"1W\X#
M!6!_Q?YE4T:P#Q[V?RN7_# 8E)/0;5';804<^'/$QB!11+IPT;OM*^%6'QXE
MLUX0L"H_:A=[*;8EVS#'W>N\R+L52]G>Y&>4J: S4E/+5GSX^6%OS7 ]JP_O
MA4W #N#+QV4&S37Y!;!#374DAA\#_2=OQ)Y@4H\=0(W;:0"";N1IMA[S8>B%
MD.28L@>'=(FJ"($*27?D(+!2[J*H9NP9\8&;G^GPH5X8\":1 $/*(Q)>!@>P
MMVH_W^:5[W?@X?X8>!@##^_)NKUH;5T':43GD\M D*R\'LIV.BSV!S[@<3::
MOW:UZJT@Z\V:.-B%W81J?8RP.AUB8@3-4U3EXH!H=N7CK9J+R0^",$6JDS ^
M09PQ+%M"!KZRBSILG?J@-RZG%RE1()'#!HSMM^5EWE2EA_L-@2Q0#M*FP^N/
MLG!?6=BJ=@5/9\L)$D/X:TX$Q.Y-ZU6Q00ZLA[Q+F:N5%<BC5$JQF?.8!+_'
MDVB#@[\_1I5/I9RV!^'.[*(C>Q?P$TV2[8%A!UIW,)X.I_Y"]U+-B_1^2TH;
M!S DYA&P9K-?;*J.0:ERN**?I*!A9C7N .<\:6D ?<7Y_UTAJ.)]\S+CJ8YV
MQSZ$VE[I]<G.$=J/>\G.I&B^,*GJOKXW;P@Q%:Y-,0 S:E5+J#Q<L8CX'VI/
M1.F[6V ]3T.1K<.'0+S^[,DF<F$7>V'E<]TP)C*4C+5!&V-0[\Q:A-J@/=IL
MHBYWID5X+9#[[>EW+46PAS8*:Z5#)"^,+_:9-0&(^2L<MW-:BW9DD_L7/N%0
M4 XME[-KN-(H&[9!+"I%QN6HJKJPH1(50[C!,!F3-,ANB_"I5XJ4:+F*'"[G
M.='@T@X*8<E3%>_9GPN(7F0WB>^^(.IN&N)+[!GW>6XTKY#Z _N$;W0@Q3BV
MNLX]?)P6EW35C$FL#R Q#M$4%VH\!/RZ@]$PQA[W\J_X2KJ<XN <D0.K/*S+
MP;BSG$.>(3%QQ: +CIV@?H'/(9-H\&P#=[C4O2'^T"<CL#/2K(+0\Y^9UX"O
MR=OT5$D#HRJOA &90,"1W#*?1Q=M)1' ,=IPD(;3!1QT"*GGS,YUTQH2A7FH
M?>^=XS+UK:P+G[H4RV3_KNSJ5QT0DI_D@,],4"U@RCA826!@9KP5:^(7$L=A
M1-N2+!IR'N*5Q) ]Q%UT6EV$7F!P#,!;[;O8@^!I21/6 !-GZR.QU2%YSN6S
M8DQ=V.?<_."52F)$S4(HG70RL[)]<J]/?-2((S;52>18_3[JKMP$H@8LPS%^
M"I2#@C(I7>^55*>R=,+^3(7]T]M[_DT66@%^Z,G-:=2 8P&)E)-?:""^$+*P
MEZ;H0HX#ARC8CLJYI*R?'E3PDLM;LKL150H%7]6G=JY%_9;30E)#DGV@:O,1
M8\>E]IZ S@L_5E5T/+ C78,?#< 1C$ OG?C.%K-(,06MD=G_)K47A6>P,\@O
M1'BT%CD<E8_]ZFHB%MY 6<RV/=?J\2,:(NY8YZW/@?:(JXGO,2+*B]1% V4A
M@108"4B)A9$"Z4/<%'-OYE<K<4QS;K7NI*3 $)_"L;K.>C]E*])=^+3)G90G
M1R+DD_E$A#ZQD]NQ:/4FN+Q\\E_0J,.<)E+(,'H5QZ[77 6%7RS.!,7)S1@Q
MPLC&D2;W@\%&28&-9M0+PD+%H0^.]I7W6 >NJB)*UXLENN2:,%<D$\CDG&LU
M8>6#*W&W"G4=1O.\XC"4O/C6Z]*^#C=IL[\RKVHLV>2NA0=KA785P(E4VX4
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M^0JH<SIRC\Y/_)]]/P=;.%KJTWEPSOB6!AZ<SL6%U$DIZ581\AR[ONU"G<
MMI>Y1U_LN("/J"^_/T"=7YJ\\'4=2*V0.I_(%^;J]Z*;SDPA490EP*91R[#&
MV6(N6@7DD;Q@4Q&9,5QY)*3?*Z9Z#$2X.!FWLC(8+0,',4-AU<*9)H^UTT:[
M!?!M;(]'9 +X?MA*\4T]L28:7(]\.8R7%7]VA)E3O_RIA%>)_5N/A/-U(L@
M$(72YYP*1%YR1P1M[ 2?EKO@.@_1/#5OI)P)';[*APFT.)6<'8U 3+AHF$%J
M>A]@]5$KJ3>ET>F\K#N-U?I2"PIW0OA$:RS81E+]Q5+7F1BTYY4\>6ZVSFD%
MVRDP5<E6'#3LG=G[6U@'16\UUI\^16(WFGVYKAKB.2BE<W!R]O)4>G"@A(V@
M"/&&VT%S=@-S!WG4NH[ 5H;8Q<:UVA-SHBY&85"-L 9B$A7P7>.AWJ=:]+4-
M,U]P^<IG !OSQA07&O,1\S@ZR1R\$T/.ZUT,-?6%HGU)$0^S_\V:+5P&AOEZ
MZ)7.+9NDWN/$VX-.C4%6V/P@_^Q0UMHD,[B(GU1K^#PF(;_ >">*ES2JZS51
M?3Z%@JZP/XT>MKZLL"J-:5]/!5V$]1//A/@0"A*'^MCMI@;CDVJA\M1)GVX@
M3_4_A.2!H*0:#K4AV=WKKPT !.%]=9312[%?8-K&Y3Y]<('N(RM 8LN6_4Z*
M!^:2H=A;Y6/LO6",J-RXH%VK$-AR9$80)>=I,!W8#W;=Q<&^"#X1Z1/-)=39
M_P41$W<R1_6>CF<ERO/<Y W#P9DVV.679R%N@IK^"N#0XD#,\6EPFJ63BJGH
MV3;IO_-D]L&1R!XNN>?+X4F)Q[ZZO)^^2HN^H>J+2D!4,*Q*"_BW^!+#69D,
MG#.;7N0# 8 0XWJDZ+T*:C& PINN ][C\6RSJ+D$&[IARZ58ON,&#6R1=>HS
MD_J6 -U # #)@7L80\%%V[5(8EQ@ST3ZG&SMRFQ"7?T0-_ 5]9A4NI*-_K[@
MW5++*S<\J&@4HIMP/R5$ 'TBSE:E/N'@0;%Y^?)8:_9Q)4>>3P;9%,Y,WEPO
MCS3SP)^BF?4 HU?]EVQH"'3=K^<D)G-G4-ZN3QS2$K C;>\1%)'@J0MJ.ZNL
M6DY:D[NS*F3\]969N6Y<J#MMVE:BO]S3AT0K;UV?.MH7BA0]5V*[Z,HB7FNI
M&RU)T+M*+FZG*LC]6CV0F[^0N.%TP3+K"YC:N(=/@#PY&PT#/LTH)9I]FM=L
M1$N1-WY9$A :PN9(NR]3N-2$UQ^/Q@C<OP,Y#,U9PD<%I[7Z<I&BMP976+-Y
MX,FQ- %.!N!;I=4-Q21U=LM9AE+STEA3TSS;WD$&;&6/^(H\9),_5SSC\S&>
M,<8SWJ]XAG=;PU?DX641/%HX1ES9@(^_40-72N_Z^X*V]([Y^CT\ZQV;5HPF
M9_XIC+F&BX.7&-7I?7<RLI*F8SCA[3%^*VL$:\(J/R<OI1[E)N!,;CW&"^V]
MKC/ *UA!]OZ8N$J'4G]?3"3J'H+"<W#U.AL.RTX'*>-=Y!+V;"$VR%&"@'K.
MO&3M,RO@V^HC?]Z=Z9LWJE.*&_]R^$'[*# FT7$RO3^FC\Y/$L[I24Q&+[L1
M,5_:LO6G?#IH\,A^+DFL+AB;L_#X"(90\QN45=M[H^%6E283 ,XX@23:%=GC
MH4RP-KJ _ZE:V[BNO'2X#'YL:2FY;?U4<ZDFXSL4"S X_6<'.]!MR"I:Y&,%
M@+>I !#5^6#ZW)6%/O&F"5-UCZL2G7[K5\U:$3WRTK<1NI+$PK:!UF&/2@3%
MD_)'BD\*&A!9[:!>E2%J@7$Y^48DV)4B)<-D  65]SF-<=Z SSL@PV7L:_!O
MR @(,&Q-IN>XE\\?J>.@:^A%/8UHP4?.N):S/FHI;NBY<GCQRPRSM8BE9@K>
M$.-T+IVO6#[X)$JN!6$S,>'[R*YOIR$Q@VD<3$[C1K@@TY*#;$)??(V?.=,C
M,W0_&MBE\TZ#KAZ4T0KM=HG_97PPILG/B#E;8-!CL#@7G_ )=IHH),Y\.F6=
MVG/&+;<S@ORTM;JMUOR OY5KL'@Y!,$I$0-VZH82%[P<RB2$MZM6<W# ;%]:
M5NB51C%S:HKZ/JNRD:ZU]83A^-O%A#1:JCNU5:6(GY*WL4 >S^K>4%ZB;@7S
M)M]R/C$?WJ.'23NBU'\OE/J;ZG7>"+W^J.H6!;&X<V<J$=%/3I)7="37 FD8
M=^CF.Q2OY6"7OH-VL3*;F:_-@E@RJQQK#BX'!RMQQQ85D?,V;E!!<^T0JY(.
MBPJ"-SM_)(6JZ7:T:Q.4TE(0WRR"I/5K77._ N*.]W_D1Q[].(((?C>?*0AB
MTK.['274GEO)S64-1<4D*ET5%F6I@%3ILQ'$ UIR4TB[0ARG- VIQ\DWCXX/
MN,\S&E.28LH%'T/R0*_+-I:-&:>Y[8W]!9U_9J9-EQY.,Y?.76RZBJ27I_F2
M/_P*D+_^\:16@+9MNZRB-AJNFVD5+9KOLT?'0FD"9V F0U.6/TSRPZ.?OCE.
M."T7_,BFW#LN.;H[0>K<6&GAK7P4J@YJ<VF'Y35Q]Y0)LY]\OF$TDI:S]?ZX
ML+<^R]1WIQ^0E!"S474LI@)82;G<@GT.I(DOMHB!-$2_XX/F+B%%L>\)+80X
MH%8NC(:N0YY<:[R+%)\*HPYF/5+37F 1COQR:8*)1-SX8$N- H[EA>;SLMPH
M/+<)&R](-5__3]TS51FW,4RTQP6SCAX@]^/]ODA%GU9+JLX*<%W:23??2 B2
MR]M&C>R3S-)*:!I_N[M7K5 M3<+7A&3SAI@C\2"B'*[:&B+R\CQI2]5K4YFT
MFQ(6F0HE]Y5VF4@!4"G(UOR3]2P_.APC4^]59.H_F8%=JY&?79A-Y&QA79P[
M56]E<DBPNT^>O]*^'*C**9?,5R?BN@*:D9F3IA$P[^+?5!P/%7W!^,QY[%(Z
M]JZUD*-$&F;"!$>]_'?3RTE+&K'4_W^PU"?>P3?A2K> ]0Y.T"2 Z<65V0/Y
MKC8"GDA-=47U+3G<'$HGH1#&!#!L%'K3XJ8'>!9^4)"EXH2B]M;\#48+A?@U
M5N1SH9W&U/"447G<TQ3AU@7PVI*&EEHIZ\UH^5 PA&W %3$X:U:3 .1EJ","
M<?@:R107 I%=6#AC?<O>54=*%G-/(9J%I.1G7"F+O=<>3'FE@UJJ;7LG\351
MEU'UTFM+:DD<4Z#[D/_G$ARH"M0!0A1XXC^L@/Q=^/;!^J7OC;WU%%X%IT7I
MN"HVW3=2VUN4&'3:$10I66("1_D^;"X"ETT4:?3/TBXJ,F!FA0UPRO)V&Z(>
MH<\!4QBC?R6FLI:L?I@L8FN0VD]T;,O+O*E*Z1&-P/8&UC'B^'['B[YM'$T#
M$H<9CHW8C16>Q8%&8G3 87+DO?45P;GRCN8\D<'D0^<CQ>S)GR)TN+8&AO6'
M.G=N !V/\]O"[U)2J[^&=3NIO"@'F6MU"S?"]I5:@D/S7F9DMJ+T72B^!1'I
M&5^Q&8ROHHY;WIB58!JDG'Z >S\_._7Q<&%<BKY5]PE9L54IK0UZ\U>:WC!Q
M:F8%L5JRNAF<$0J*[[XR9"UH)V0)MRI[&PKMT$*>IQUR3\;0PN_L9S[U(05M
M+VY8YTH-^)DOZ<XL3!*7,VE^$$I-2L8FA"UXH(79P6H=7U!Q/&F=/$'(F"R4
M%U#.)E>^_IZ+VG"%N=T_)<?<RS@4&L85&4RQ<Q]:-\EECBR;-D$ZT8*;(U>I
M%.SEJ>!!="^] Y+4EGE];0=-X8P^ PBN<=<5K?/'&3)VI,'?P9C6<G0J<+7C
MT+9U#9+Z9X=&0J(+'73U-.' V':++ZA1$6<31K8R</%6F=DHKH(VD?UN+.X]
M5Z)UTY;S\A#B1X[;NMCH@22A<3GQ1+),"C<:>F]KZ+V_K[&CZQ%'PJ>*5.@#
M=,B71"HN=_)%VGS- !2Q4-,&Q@Q395 [MT@PPEP&*NT3;ZJ26\YTI2;4#*F7
M'5)2]U:R_+64&, ]Q,ZZ.M8'0SJOHJ!(O>6JZ#QG\3ME.R:I"6XRU_$DO"4W
MC H_()>0#%,ITMFWA$/+%I1U  )Q7.9_$?4BRH*8< %3&=72T.K8G-K&$$S?
M"3MN+I&<W88B)9WQBLI%Z.(_?H?>\QC1T1@C&F-$[\FZW3CMT;MS)K[0&D=Z
MT%QS534E>^Q>V2M6B+9F]EPJ4GY?(>G5+061!:<@U-6-B JQB0!#3;TG<F;9
MMRTR_XFIZTWRTA)-PPWPB"X?]_Q?E"I/3>;;$RQHBHQ04=@#V9!IT64,XJ>M
MN<W?<#GKU'<F&)9^VDB?C4;3EMD/@M]0$0!B"8D/55G:] K"\CWG_'?_.,[_
MQ1WT1(0 N+-L5P7]\7]02P$"% ,4    " #:,W!3O]?R,[$0   [$0  %@
M            @ $     9S)Q<G9Z>#!U;#%B,# P,# Q+FIP9U!+ 0(4 Q0
M   ( -HS<%/#1>EQMP0  'H6   1              "  >40  !T>&UD+3(P
M,C$Q,3$Q+GAS9%!+ 0(4 Q0    ( -HS<%,7U_Z]2 <  +A.   5
M      "  <L5  !T>&UD+3(P,C$Q,3$Q7VQA8BYX;6Q02P$"% ,4    " #:
M,W!3/E4H_BD%  #C+@  %0              @ %&'0  ='AM9"TR,#(Q,3$Q
M,5]P<F4N>&UL4$L! A0#%     @ VC-P4Z *D I/$P  (IH  !4
M     ( !HB(  '1X;60M.&MA7S(P,C$Q,3$Q+FAT;5!+ 0(4 Q0    ( -HS
M<%.,=7ET738  !%# 0 1              "  20V  !T>&UD+65X.3DQ7S$V
:+FAT;5!+!08     !@ & (L!  "P;      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
